Pliant Therapeutics, Inc. · NASDAQ:PLRX

Pliant Therapeutics — ERS International Congress 2023

18 slides from Pliant Therapeutics's conference presentation, Sep 10, 2023

1. Slide 1: Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF study

   42463 Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF study (NCT04396756) Wuyts WA, Valenzuela C, Jenkins G, Goldin JG, Kim GJ, Jurek M, Turner S, Decaris M, Barnes CN, Lefebvre É, Cosgrove G, Cottin V SEPTEMBER 10, 2023 © 2023 PLIANT THERAPEUTICS

2. Slide 2: Conflict of interest disclosure

   Conflict of interest disclosure ❑ I have no real or perceived conflicts of interest that relate to this presentation. ✓ I have the following real or perceived conflicts of interest that relate to this presentation: ❑ Affiliation/Financial interest Commercial company Grants/research support: Roche, B

3. Slide 3: Disclaimers

   Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the “Company”). The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of th

4. Slide 4: αvβ6 and αvβ1 integrins drive cell-matrix interactions in fibrosis

   αvβ6 and αvβ1 integrins drive cell-matrix interactions in fibrosis αvβ6 and αvβ1 integrins promote fibrosis • TGF-b is a central mediator of fibrosis1,2 through activation of TGF-β1,2 • Systemic TGF-b blockade carries toxicity risks2 Bexotegrast • Activation of latent TGF-b by αvβ6 (lung (PLN-74809)

5. Slide 5: Phase 2a INTEGRIS-IPF study – 12-week analyses

   Phase 2a INTEGRIS-IPF study – 12-week analyses FVC change from Baseline to Week 12 • Bexotegrast was well tolerated across all dose (MMRM analysis) (efficacy mITT populationa) groups over 12 weeks of treatment; most TEAEs were mild to moderate in severity, with no drug- Bexotegrast 320 mg related SA

6. Slide 6: Aims and objectives

   Aims and objectives To present Week 24 results from INTEGRIS-IPF (NCT04396756) for the safety, tolerability, and durability of effects on FVC and QLF of bexotegrast 320 mg in participants with IPF Purpose of evaluating longer term treatment with bexotegrast 320 mg • Safety and tolerability of the hi

7. Slide 7: INTEGRIS-IPF study design and endpoints

   INTEGRIS-IPF study design and endpoints Bexotegrast Bexotegrast 40 mg (N=22) END OF STUDY Bexotegrast 80 mg (N=23) SCREENING 3:1 Randomization Bexotegrast 160 mg (N=22) Bexotegrast 320 mg (N=21) N=21 Pooled Placebo (N=31) N=8 Placebo Stratified for use of background therapy (Y/N) Day -28 Baseline We

8. Slide 8: Baseline demographics and disease characteristics – bexotegrast 320 mg cohort

   Baseline demographics and disease characteristics – bexotegrast 320 mg cohort Participants, n (%) Bexotegrast 320 mg Placebo Demographics (N=22)a (N=8)a Male sex, n (%) 21 (95.5) 5 (62.5) Mean age, years (SD) 70.5 (7.14) 73.3 (7.98) Mean time since IPF diagnosis, months (SD) 34.4 (28.97) 41.6 (32.56

9. Slide 9: Safety summary—bexotegrast 320 mg cohort

   Safety summary—bexotegrast 320 mg cohort Participants, n (%) Bexotegrast 320 mg Placebo Participants with any: (N=22)a (N=8)a TEAE 20 (90.9) 7 (87.5) TEAE related to study drug​ 5 (22.7) 2 (25.0) Grade ≥3 TEAEb 5 (22.7) 1 (12.5) Grade ≥3 TEAE related to study drug​ 1 (4.5)c 0 (0.0) SAE 2 (9.1) 1 (12

10. Slide 10: Most frequently reported TEAEs were not related to study drug – bexotegrast 320 mg cohort

    Most frequently reported TEAEs were not related to study drug – bexotegrast 320 mg cohort Bexotegrast 320 mg Placebo AE, n (%) of Participants Reporting (N=22) (N=8) Most frequent TEAEs (>10% in at least one arm and n >1 participant) Diarrhea 7 (31.8) 3 (37.5) Related to study drug​​ 4 (18.2) 0 Dysp

11. Slide 11: FVC change from Baseline to Week 24: ITT population and background therapy subgroup

    FVC change from Baseline to Week 24 ITT population and background therapy subgroup ITT population Background therapy subgroup Bexotegrast reduced FVC decline Bexotegrast + a background therapy reduced by 67% relative to placebo at Week 24 FVC decline by 80% relative to a background therapy alone at

12. Slide 12: FVC change at Week 24: ITT population

    FVC change at Week 24 ITT population FVC change data suggest a persistent treatment effect from 12 to 24 weeks with bexotegrast 320 mg Participants with missing data are not included here FVC, forced vital capacity; ITT, intent-to-treat © 2023 PLIANT THERAPEUTICS 12

13. Slide 13: Change in QLF score and stabilization/improvement in fibrosis

    Change in QLF scorea change from Baseline and stabilization/improvement in fibrosis Per CT protocol populationb Change in QLF score Stabilization/improvement in fibrosis 100 QLF improved/stable or worsening QLFd 71% Proportion of participants with improved/stable from Baseline at Week 24 (%) 50 from

14. Slide 14: Conclusions and future research

    Conclusions and future research Bexotegrast 320 mg was well tolerated in participants with IPF for up to 40 weeks of treatment • Most TEAEs were mild or moderate in severity • No discontinuations due to TEAEs occurred from Week 12 to Week 40 • No drug-related SAEs were reported There was evidence of

15. Slide 15: BEACON-IPF study design

    BEACON-IPF study design PRIMARY ENDPOINT • Change from baseline in absolute FVC (mL) Randomization 1:1:1 at Week 52 END OF STUDY Placebo (n=89) SCREENING SECONDARY ENDPOINTS Bexotegrast 160 mg (n=89) • Time to disease progression (≥10% absolute decline from baseline Bexotegrast 320 mg (n=89) in FVCp

16. Slide 16: Acknowledgements

    Acknowledgements • Thank you to the clinical site staff and the patients who participated in this study • The INTEGRIS-IPF study was sponsored by Pliant Therapeutics, Inc. • Thank you to Hardean E Achneck, MD (Senior Vice President, Head of Clinical Development at Pliant Therapeutics, Inc.) and Anni

17. Slide 17: References

    References • Decaris ML, Schaub JR, Chen C, et al. Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res 2021;22(1):265 • Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacer

18. Slide 18: Please use the QR codes shown to download a copy of the ePoster

    Please use the QR codes shown to download a copy of the ePoster (OA1423) pliantrx.com live.ersnet.org The ERS is not responsible for and does not endorse the data and information presented on external sites © 2023 PLIANT THERAPEUTICS

Pliant Therapeutics — ERS International Congress 2023 on 6ix